Weaving along Hawaii's Na Pali Coast is the famous, breathtaking Kalalau trail. This trail is not only notable for its strenuous path and terrain that is difficult to traverse but also known for its unsurpassed beauty. Kalalau was early inspiration for us, today representing out innovative spirit and deep commitment to advancing the treatment of eye diseases.
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases.
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases.
Location: United States, Massachusetts, Arlington
Employees: 51-200
Total raised: $218.2M
Founded date: 2009
Investors 8
Funding Rounds 5
| Date | Series | Amount | Investors |
| 02.10.2018 | - | $110M | - |
| 13.04.2016 | Series C | $68M | - |
| 23.04.2014 | Series B | $22.5M | - |
| 28.02.2013 | Series A | $11.5M | - |
| 14.03.2012 | - | $6.2M | - |
Mentions in press and media 24
| Date | Title | Description |
| 28.11.2022 | Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing | - |
| 15.11.2021 | Kala Pharmaceuticals Announces Time Change for Third Quarter 2021 Financial Results Conference Call | WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of t... |
| 15.11.2021 | Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Dise... | -- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing -- -- KPI-012 demonstrated positive safety and efficacy results in... |
| 21.07.2017 | Kala Pharmaceuticals, compañía participada por Ysios, anuncia su salida a bolsa en el Nasdaq | 21/07/2017 Nota de prensa KALA PHARMACEUTICALS, COMPAÑÍA PARTICIPADA POR YSIOS CAPITAL, ANUNCIA SU SALIDA A BOLSA EN EL NASDAQ. La entidad de capital riesgo (venture capital) Ysios Capital, ha anunciado hoy la salida a bolsa vía una ofer... |
| 07.06.2016 | Longitude Capital raises $525M for third fund spanning early to late stage medtech investments | The investment firm expects to invest an average of $15 million to 25 million per investment in approximately 25 companies. It raised $385 million for its second fund in 2012. Galletti highlighted some of the technologies in which it has de... |
| 14.04.2016 | Kala Pharmaceuticals cierra una ronda de $68 millones, acude Ysios Capital | 14/04/2016 KALA PHARMACEUTICALS CIERRA UNA RONDA DE $68 MILLONES, ACUDE YSIOS CAPITAL. La gestora de capital riesgo (venture capital) líder en inversiones en el sector biotecnológico Ysios Capital, ha anunciado hoy su participación en la ... |
| 13.04.2016 | Kala Pharmaceuticals Closes $68M Series C Financing | Kala Pharmaceuticals, Inc., a Waltham, MA-based developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, closed $68m Series C financing. The round was led by Longitude Capital with pa... |
| 13.04.2016 | Kala Pharmaceuticals Closes $68M in Series C | WALTHAM, MA, Developer of ophthalmic products based on muscle-penetrating particle technology, has raised $68 million in Series C funding. >> Click here for more funding data on Kala Pharmaceuticals >> To export Kala Pharmac... |
| 12.02.2015 | Will the $350M fund Lux Capital is raising include digital health and biotech investments? | HIPAA compliance Aptible automates HIPAA compliance for Web-based and mobile applications. It manages servers, security, backups, encryption, and organizational permissions and helps them demonstrate proof of compliance. Big data Kyruus use... |
| 25.04.2014 | Using nanoparticles, not needles, to deliver drugs into the eye nets Kala Pharmaceuticals $22.5M | An aging population is fueling healthy growth in the ophthalmology drug market, led by Pfizer, Allergan, Alcon, Novartis, Merck and Roche, and investors are betting big on new treatments. Kala, for one, just pulled in a $22.5 million Series... |
Show more